Skip to main content
Erschienen in: Virchows Archiv 1/2007

01.07.2007 | Original Article

Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions

verfasst von: Natalia S. Pellegata, Leticia Quintanilla-Martinez, Gisela Keller, Sandya Liyanarachchi, Heinz Höfler, Michael J. Atkinson, Falko Fend

Erschienen in: Virchows Archiv | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Pheochromocytomas are neuroendocrine tumors arising in the neural crest-derived chromaffin cells of the adrenal gland or in extra-adrenal sympathetic ganglia (paragangliomas). In a rat model of multiple endocrine neoplasia (MEN), absence of functional p27Kip1 protein predisposes to pheochromocytoma and paraganglioma development. As no data is available regarding the involvement of p27Kip1 in human pheochromocytoma and/or paraganglioma, we set out to determine the expression pattern of p27Kip1 in those tumor types. A panel of 25 pheochromocytomas and 23 paragangliomas was collected. Two pheochromocytomas were from MEN2 patients. The paragangliomas included 15 tumors that developed at the carotid bifurcation, three in the jugulo–tympanic area, and five at other sites. Except for the MEN2 cases, all others were apparently sporadic. Immunohistochemistry for p27Kip1 and the proliferation marker Ki67 was performed. We found that p27Kip1 expression is reduced/lost in 56% of pheochromocytomas, but only in 18.1% of paragangliomas. Downregulation of p27Kip1 was not associated with increased proliferation. Cases showing reduced/lost p27Kip1 expression were screened for the presence of somatic mutations in CDKN1B (p27Kip1) and for allelic imbalance at the p27Kip1 locus. Three cases had allelic imbalance but none had mutations. In conclusion, pheochromocytomas display extreme reduction/loss of p27Kip1 expression at high frequency.
Literatur
1.
Zurück zum Zitat Adesina AM, Dunn ST, Moore WE, Nalbantoglu J (2000) Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival. Pathol Res Pract 196:243–250PubMed Adesina AM, Dunn ST, Moore WE, Nalbantoglu J (2000) Expression of p27kip1 and p53 in medulloblastoma: relationship with cell proliferation and survival. Pathol Res Pract 196:243–250PubMed
2.
Zurück zum Zitat Agathanggelou A, Cooper WN, Latif F (2005) Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65:3497–3508PubMedCrossRef Agathanggelou A, Cooper WN, Latif F (2005) Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65:3497–3508PubMedCrossRef
3.
Zurück zum Zitat Alkarain A, Slingerland J (2004) Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 6:13–21PubMedCrossRef Alkarain A, Slingerland J (2004) Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Res 6:13–21PubMedCrossRef
4.
Zurück zum Zitat Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F (2001) RASSF1A promoter region CpG island hypermethylation in pheochromocytomas and neuroblastoma tumours. Oncogene 20:7573–7577PubMedCrossRef Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F (2001) RASSF1A promoter region CpG island hypermethylation in pheochromocytomas and neuroblastoma tumours. Oncogene 20:7573–7577PubMedCrossRef
5.
Zurück zum Zitat Astuti D, Hart-Holden N, Latif F, Lalloo F, Black GC, Lim C, Moran A, Grossman AB, Hodgson SV, Freemont A, Ramsden R, Eng C, Evans DG, Maher ER (2003) Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol 59:728–733CrossRef Astuti D, Hart-Holden N, Latif F, Lalloo F, Black GC, Lim C, Moran A, Grossman AB, Hodgson SV, Freemont A, Ramsden R, Eng C, Evans DG, Maher ER (2003) Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol 59:728–733CrossRef
6.
Zurück zum Zitat Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51–63PubMedCrossRef Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A (2005) p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7:51–63PubMedCrossRef
7.
Zurück zum Zitat Bauters C, Vantyghem MC, Leteurtre E, Odou MF, Mouton C, Porchet N, Wemeau JL, Proye C, Pigny P (2003) Hereditary pheochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet 40:e75PubMedCrossRef Bauters C, Vantyghem MC, Leteurtre E, Odou MF, Mouton C, Porchet N, Wemeau JL, Proye C, Pigny P (2003) Hereditary pheochromocytomas and paragangliomas: a study of five susceptibility genes. J Med Genet 40:e75PubMedCrossRef
8.
Zurück zum Zitat Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18:862–876PubMedCrossRef Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18:862–876PubMedCrossRef
9.
Zurück zum Zitat Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C (2001) p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 32:1094–1101PubMedCrossRef Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C (2001) p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 32:1094–1101PubMedCrossRef
10.
Zurück zum Zitat Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A (1996) Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56:3331–3337PubMed Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A (1996) Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56:3331–3337PubMed
11.
Zurück zum Zitat Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–230PubMedCrossRef Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–230PubMedCrossRef
12.
Zurück zum Zitat Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, Inghirami G (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619–626PubMed Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, Inghirami G (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95:619–626PubMed
13.
Zurück zum Zitat Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G (2002) S-phase kinase-associated protein 2 expression in non-Hodgkin’s lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 160:1457–1466PubMed Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G (2002) S-phase kinase-associated protein 2 expression in non-Hodgkin’s lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 160:1457–1466PubMed
14.
Zurück zum Zitat Dahia PL (2006) Evolving concepts in pheochromocytoma and paraganglioma. Curr Opin Oncol 18:1–8PubMedCrossRef Dahia PL (2006) Evolving concepts in pheochromocytoma and paraganglioma. Curr Opin Oncol 18:1–8PubMedCrossRef
15.
Zurück zum Zitat Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, Magoffin D, Aronin N, Cascon A, Hayashida CY, Li C, Toledo SP, Stiles CD, Familial Pheochromocytoma Consortium (2005) Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res 65:9651–9658PubMedCrossRef Dahia PL, Hao K, Rogus J, Colin C, Pujana MA, Ross K, Magoffin D, Aronin N, Cascon A, Hayashida CY, Li C, Toledo SP, Stiles CD, Familial Pheochromocytoma Consortium (2005) Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res 65:9651–9658PubMedCrossRef
16.
Zurück zum Zitat Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72–80PubMedCrossRef Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1:72–80PubMedCrossRef
17.
Zurück zum Zitat Dammann R, Schagdarsurengin U, Seidel C, Trumpler C, Hoang-Vu C, Gimm O, Dralle H, Pfeifer GP, Brauckhoff M (2005) Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas. Exp Clin Endocrinol Diabetes 113:1–7PubMedCrossRef Dammann R, Schagdarsurengin U, Seidel C, Trumpler C, Hoang-Vu C, Gimm O, Dralle H, Pfeifer GP, Brauckhoff M (2005) Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas. Exp Clin Endocrinol Diabetes 113:1–7PubMedCrossRef
18.
Zurück zum Zitat Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423–436PubMedCrossRef Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423–436PubMedCrossRef
19.
Zurück zum Zitat Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381–3385PubMed Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381–3385PubMed
20.
Zurück zum Zitat Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y (1998) CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899–2911PubMedCrossRef Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y (1998) CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899–2911PubMedCrossRef
21.
Zurück zum Zitat Fritz A, Walch A, Piotrowska K, Rosemann M, Schaffer E, Weber K, Timper A, Wildner G, Graw J, Hofler H, Atkinson MJ (2002) Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62:3048–3051PubMed Fritz A, Walch A, Piotrowska K, Rosemann M, Schaffer E, Weber K, Timper A, Wildner G, Graw J, Hofler H, Atkinson MJ (2002) Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62:3048–3051PubMed
22.
Zurück zum Zitat Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359:295–300PubMedCrossRef Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359:295–300PubMedCrossRef
23.
Zurück zum Zitat Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr, Lloyd RV (1997) Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509–519PubMed Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr, Lloyd RV (1997) Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 151:509–519PubMed
24.
Zurück zum Zitat Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266–2269PubMed Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266–2269PubMed
25.
Zurück zum Zitat Kibel AS, Faith DA, Bova GS, Isaacs WB (2000) Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol 164:192–196PubMedCrossRef Kibel AS, Faith DA, Bova GS, Isaacs WB (2000) Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol 164:192–196PubMedCrossRef
26.
Zurück zum Zitat Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288–294PubMedCrossRef Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A (1992) Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288–294PubMedCrossRef
27.
Zurück zum Zitat Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX (2005) Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 11:4587–4591PubMed Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX (2005) Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 11:4587–4591PubMed
28.
Zurück zum Zitat Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323PubMed Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323PubMed
29.
Zurück zum Zitat Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–234PubMedCrossRef Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–234PubMedCrossRef
30.
Zurück zum Zitat Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP (1995) Alterations of the p27KIP1 gene in non-Hodgkin’s lymphomas and adult T-cell leukemia/lymphoma. Blood 86:1924–1930PubMed Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP (1995) Alterations of the p27KIP1 gene in non-Hodgkin’s lymphomas and adult T-cell leukemia/lymphoma. Blood 86:1924–1930PubMed
31.
Zurück zum Zitat Nakatsuka S, Liu A, Yao M, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Aozasa K (2003) Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. Int J Oncol 22:561–568PubMed Nakatsuka S, Liu A, Yao M, Takakuwa T, Tomita Y, Hoshida Y, Nishiu M, Aozasa K (2003) Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies. Int J Oncol 22:561–568PubMed
32.
Zurück zum Zitat Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C; Freiburg–Warsaw–Columbus Pheochromocytoma Study Group (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466PubMedCrossRef Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C; Freiburg–Warsaw–Columbus Pheochromocytoma Study Group (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466PubMedCrossRef
33.
Zurück zum Zitat Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682–685PubMedCrossRef Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682–685PubMedCrossRef
34.
Zurück zum Zitat Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558–15563PubMedCrossRef Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558–15563PubMedCrossRef
35.
Zurück zum Zitat Piotrowska K, Pellegata NS, Rosemann M, Fritz A, Graw J, Atkinson MJ (2004) Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome 15:135–141PubMedCrossRef Piotrowska K, Pellegata NS, Rosemann M, Fritz A, Graw J, Atkinson MJ (2004) Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm Genome 15:135–141PubMedCrossRef
36.
Zurück zum Zitat Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66PubMedCrossRef Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59–66PubMedCrossRef
37.
Zurück zum Zitat Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Hofler H, Fend F (2003) Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162:1449–1461PubMed Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, Hofler H, Fend F (2003) Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162:1449–1461PubMed
38.
Zurück zum Zitat Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP (1996) p27/Kip1 mutation found in breast cancer. Cancer Res 56:2400–2404PubMed Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP (1996) p27/Kip1 mutation found in breast cancer. Cancer Res 56:2400–2404PubMed
39.
Zurück zum Zitat Toyoshima H, Hunter T (1994) p27Kip1, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74PubMedCrossRef Toyoshima H, Hunter T (1994) p27Kip1, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67–74PubMedCrossRef
40.
Zurück zum Zitat van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, Oosterwijk E (2005) Prevalence of von Hippel–Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5:57PubMedCrossRef van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, Schouten LJ, Gorissen HJ, Schalken JA, van den Brandt PA, Oosterwijk E (2005) Prevalence of von Hippel–Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5:57PubMedCrossRef
41.
Zurück zum Zitat Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T (1994) Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 13:4251–4259PubMed Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T (1994) Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 13:4251–4259PubMed
42.
Zurück zum Zitat Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL (2006) Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 66:2162–2172PubMedCrossRef Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL (2006) Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res 66:2162–2172PubMedCrossRef
Metadaten
Titel
Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions
verfasst von
Natalia S. Pellegata
Leticia Quintanilla-Martinez
Gisela Keller
Sandya Liyanarachchi
Heinz Höfler
Michael J. Atkinson
Falko Fend
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 1/2007
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-007-0431-6

Weitere Artikel der Ausgabe 1/2007

Virchows Archiv 1/2007 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …